Get the Stockscreener App
21.88
2.64%
-0.5889
Enliven Therapeutics Inc stock is traded at $21.88, with a volume of 70,641.
It is down -2.64% in the last 24 hours and down -8.32% over the past month.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
See More
Previous Close:
$22.47
Open:
$22.39
24h Volume:
70,641
Relative Volume:
0.31
Market Cap:
$1.10B
Revenue:
-
Net Income/Loss:
$-85.21M
P/E Ratio:
-11.58
EPS:
-1.89
Net Cash Flow:
$-68.53M
1W Performance:
+0.07%
1M Performance:
-8.32%
6M Performance:
+0.95%
1Y Performance:
+43.73%
1-Day Range:
$21.75
$22.39
1-Week Range:
$21.28
$23.18
52-Week Range:
$10.90
$30.03
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Name
Enliven Therapeutics Inc
Sector
Industry
Phone
720-647-8519
Address
6200 LOOKOUT ROAD, BOULDER
Compare ELVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
21.87 | 1.10B | 0 | -85.21M | -68.53M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.36 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.63 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
650.90 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.84 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.71 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-24 | Initiated | BTIG Research | Buy |
| Sep-09-24 | Initiated | H.C. Wainwright | Buy |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-09-24 | Initiated | Mizuho | Buy |
| Mar-29-23 | Initiated | Jefferies | Buy |
Enliven Therapeutics Inc Stock (ELVN) Latest News
Trend Tracker for (ELVN) - Stock Traders Daily
Enliven Therapeutics: Promising Innovations in Tyrosine Kinase Inhibitors and Strategic Growth Plans Justify Buy Rating - TipRanks
SG Americas Securities LLC Increases Stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Strong Buy Recommendation for Enliven Therapeutics Due to ELVN-001’s High Selectivity and Promising Clinical Data - TipRanks
Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 3,250 Shares - MarketBeat
Enliven Therapeutics CFO sells $70,177 in stock - MSN
Enliven Therapeutics (NASDAQ:ELVN) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Enliven Therapeutics (NASDAQ:ELVN) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Objective long/short (ELVN) Report - Stock Traders Daily
Enliven Therapeutics (NASDAQ:ELVN) Shares Up 11.3%Here's Why - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Sees Strong Trading VolumeStill a Buy? - MarketBeat
Barclays PLC Acquires 42,012 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells $524,706.00 in Stock - MarketBeat
Anish Patel, COO of Enliven Therapeutics, sells $685,868 in stock By Investing.com - Investing.com Nigeria
Anish Patel, COO of Enliven Therapeutics, sells $685,868 in stock - Investing.com
Enliven Therapeutics (NASDAQ:ELVN) Trading Down 9.8%Time to Sell? - MarketBeat
Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 1,000 Shares - MarketBeat
Enliven's Early Data Stands Out From Peers (NASDAQ:ELVN) - Seeking Alpha
Enliven Therapeutics (ELVN) Price Target Increased by 10.75% to 35.02 - MSN
(ELVN) Trading Advice - Stock Traders Daily
Jane Street Group LLC Sells 22,212 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Jane Street Group LLC Cuts Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Shares Up 7.6%Here's What Happened - MarketBeat
Enliven Therapeutics Inc (NASDAQ: ELVN) Stock Forecast: Bearish Sentiment Points To -75.56% Downside In 2025 - Stocks Register
Enliven Therapeutics CFO sells shares worth $94,474 - Investing.com India
Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells 3,350 Shares of Stock - MarketBeat
Franklin Resources Inc. Invests $559,000 in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Barclays PLC Has $1.44 Million Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Barclays PLC Has $1.44 Million Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Geode Capital Management LLC Boosts Stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Geode Capital Management LLC Purchases 67,813 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Trading Down 2.9%Here's Why - MarketBeat
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Position Increased by State Street Corp - Defense World
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Wellington Management Group LLP Raises Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Lord Abbett & CO. LLC Takes Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
The Manufacturers Life Insurance Company Increases Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
BTIG Research Initiates Coverage on Enliven Therapeutics (NASDAQ:ELVN) - Defense World
When the Price of (ELVN) Talks, People Listen - Stock Traders Daily
Enliven Therapeutics (NASDAQ:ELVN) Now Covered by BTIG Research - MarketBeat
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Acquired by Charles Schwab Investment Management Inc. - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Up 6.8%Should You Buy? - MarketBeat
Janus Henderson Group PLC Purchases 313,019 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Sold by RA Capital Management L.P. - MarketBeat
Patient Square Capital LP Takes $2.31 Million Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Enliven Therapeutics Inc Stock (ELVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Enliven Therapeutics Inc Stock (ELVN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hohl Benjamin | CHIEF FINANCIAL OFFICER |
Jan 27 '25 |
Sale |
21.59 |
3,250 |
70,178 |
13,000 |
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):